Puthiyaveettil N Raghunath
Overview
Explore the profile of Puthiyaveettil N Raghunath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Salem M, Raghunath P, Marzec M, Liu X, Kasprzycka M, Robertson E, et al.
Am J Pathol
. 2009 Jul;
175(2):817-24.
PMID: 19608873
Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29...
2.
Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M, et al.
Proc Natl Acad Sci U S A
. 2008 Dec;
105(52):20852-7.
PMID: 19088198
The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the...
3.
Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath P, El-Salem M, et al.
Blood
. 2007 Nov;
111(4):2181-9.
PMID: 18025151
We examined functional status, activation mechanisms, and biologic role of the mTORC1 signaling pathway in malignant CD4(+) T cells derived from the cutaneous T-cell lymphoma (CTCL). Whereas the spontaneously growing...
4.
El-Salem M, Raghunath P, Marzec M, Wlodarski P, Tsai D, Hsi E, et al.
Lab Invest
. 2006 Nov;
87(1):29-39.
PMID: 17075574
We examined activation of the mTOR signaling pathway in situ in the primary, normal reactive and patient-derived post-transplant lymphoproliferative disorder (PTLD) tissue samples. We accomplished this analysis by immunohistochemistry on...
5.
Zhang Q, Wang H, Woetmann A, Raghunath P, Odum N, Wasik M
Blood
. 2006 Jul;
108(3):1058-64.
PMID: 16861352
In this study, we demonstrated that STAT3, a well-characterized transcription factor expressed in continuously activated oncogenic form in the large spectrum of cancer types, induces in malignant T lymphocytes the...
6.
Zhang Q, Wang H, Marzec M, Raghunath P, Nagasawa T, Wasik M
Proc Natl Acad Sci U S A
. 2005 May;
102(19):6948-53.
PMID: 15870198
Expression of SHP-1 phosphatase, a key negative regulator of cell signaling, is lost in T cell lymphomas and other malignancies due to DNA methylation of the SHP-1 promoter by a...
7.
Narula N, Narula J, Zhang P, Haider N, Raghunath P, Brittin R, et al.
Ann Thorac Surg
. 2005 Mar;
79(4):1333-7.
PMID: 15797072
Background: Myofibrillarlytic (MFL) cells are commonly observed in subendocardial myocardium in myocardial infarction. Because ischemic damage to myocytes is also known to induce apoptosis, we evaluated the prevalence of apoptosis...
8.
Genega E, Kapali M, Torres-Quinones M, Huang W, Knauss J, Wang L, et al.
Mod Pathol
. 2004 Oct;
18(1):11-8.
PMID: 15475938
The classification of urothelial neoplasms of the kidney traditionally has been similar to that of urinary bladder tumors. Several years ago, the classification of papillary urothelial neoplasms was revised. The...
9.
Acs G, Wang L, Raghunath P, Salscheider M, Zhang P
Appl Immunohistochem Mol Morphol
. 2003 Sep;
11(3):222-9.
PMID: 12966348
Immunohistochemical (IHC) detection of HER-Z overexpression by HercepTest on paraffin sections has been proposed for selecting patients with metastatic breast carcinoma for Herceptin therapy. Interpretation of intermediate (2+) reactivity could...